
Daniel M Altmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3562140/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature, 2022, 601, 110-117.	27.8	280
2	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	12.6	91
3	Vaccine efficacy and immune interference: co-administering COVID-19 and influenza vaccines. Lancet Respiratory Medicine,the, 2022, 10, 125-126.	10.7	2
4	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
5	Rapid synchronous type 1 IFN and virus-specific TÂcell responses characterize first wave non-severe SARS-CoV-2 infections. Cell Reports Medicine, 2022, 3, 100557.	6.5	36
6	HLAâ€DR polymorphism in SARSâ€CoVâ€2 infection and susceptibility to symptomatic COVIDâ€19. Immunology, 2022, 166, 68-77.	4.4	18
7	COVID-19 vaccination: The road ahead. Science, 2022, 375, 1127-1132.	12.6	134
8	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
9	Regulatory T cells in acute and chronic human Chikungunya infection. Microbes and Infection, 2022, 24, 104927.	1.9	6
10	Meningeal lymphatic vessels mediate neurotropic viral drainage from the central nervous system. Nature Neuroscience, 2022, 25, 577-587.	14.8	43
11	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) Tj ETQq1 1 0.78	34314 rgB	T ³ Overlock
12	Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science, 2022, 377, .	12.6	241
13	Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine,the, 2022, 10, 840-850.	10.7	52
14	Decoding the unknowns in long covid. BMJ, The, 2021, 372, n132.	6.0	44
15	Immunity to SARS-CoV-2 variants of concern. Science, 2021, 371, 1103-1104.	12.6	169
16	Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet, The, 2021, 397, 1057-1058.	13.7	360
17	Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. Journal of Infection, 2021, 82, 399-406.	3.3	106
18	Risk of SARS-CoV-2 reinfection after natural infection. Lancet, The, 2021, 397, 1161-1163.	13.7	53

#	Article	IF	CITATIONS
19	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection. EBioMedicine, 2021, 65, 103259.	6.1	61
20	Children and the return to school: how much should we worry about covid-19 and long covid?. BMJ, The, 2021, 372, n701.	6.0	8
21	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423.	12.6	286
22	SARS-CoV-2 variants: Subversion of antibody response and predicted impact on TÂcell recognition. Cell Reports Medicine, 2021, 2, 100286.	6.5	18
23	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	6.0	198
24	COVIDâ€19 vaccines: what do we know so far?. FEBS Journal, 2021, 288, 4996-5009.	4.7	7
25	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy , 2021, 9, e003311.		66
26	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
27	Phenotypical characterization of regulatory T cells in acute Zika infection. Cytokine, 2021, 146, 155651.	3.2	5
28	Waning immunity to SARS-CoV-2: implications for vaccine booster strategies. Lancet Respiratory Medicine,the, 2021, 9, 1356-1358.	10.7	35
29	The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?. Nature Reviews Immunology, 2021, 21, 762-768.	22.7	80
30	Covid-19 caseload in the UKâ \in "assessments and mitigations. BMJ, The, 2021, 375, n2843.	6.0	2
31	SARS-Cov-2 immune waning and reinfection in care-home settings. The Lancet Healthy Longevity, 2021, 2, e776-e777.	4.6	0
32	Narrating the natural history of live infection by SARS CoV-2 VOC in animal models. EBioMedicine, 2021, 74, 103704.	6.1	2
33	Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. Lancet, The, 2021, 398, 2057-2059.	13.7	19
34	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	12.6	10
35	BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis. Frontiers in Immunology, 2021, 12, 767359.	4.8	6
36	A new immunology forum for a new age of immunology. Oxford Open Immunology, 2020, 1, .	2.8	0

#	Article	IF	CITATIONS
37	SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Science Immunology, 2020, 5, .	11.9	240
38	Multiplexed gene expression analysis of HLA class II-associated podoconiosis implicates chronic immune activation in its pathogenesis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 926-936.	1.8	4
39	Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. Acta Neuropathologica, 2020, 140, 143-167.	7.7	48
40	Strong CD4 T Cell Responses to Zika Virus Antigens in a Cohort of Dengue Virus Immune Mothers of Congenital Zika Virus Syndrome Infants. Frontiers in Immunology, 2020, 11, 185.	4.8	12
41	Adaptive immunity to SARS-CoV-2. Oxford Open Immunology, 2020, 1, iqaa003.	2.8	10
42	What policy makers need to know about COVID-19 protective immunity. Lancet, The, 2020, 395, 1527-1529.	13.7	188
43	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology, 2020, 5, .	11.9	172
44	Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. ELife, 2020, 9, .	6.0	26
45	Antibiotic therapy and outcome from immune-checkpoint inhibitors. , 2019, 7, 287.		77
46	Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12964-12973.	7.1	59
47	â€Just 17 if you know what I mean' … but what do we really mean to say about Th17 immunity?. Immunology, 2019, 156, 297-298.	4.4	0
48	Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut, 2019, 68, 1430-1438.	12.1	235
49	Knowns and unknowns of tissueâ€resident memory T cells. Immunology, 2019, 157, 1-2.	4.4	1
50	The immune regulatory role of neutrophils. Immunology, 2019, 156, 215-216.	4.4	9
51	Bioluminescent Reporting of In Vivo IFN-γ Immune Responses during Infection and Autoimmunity. Journal of Immunology, 2019, 202, 2502-2510.	0.8	8
52	Natural killer cell transcriptional control, subsets, receptors and effector function. Immunology, 2019, 156, 109-110.	4.4	1
53	Tâ€cell immunology of the lung: maintaining the balance between host defence and immune pathology. Immunology, 2019, 156, 1-2.	4.4	4
54	Progressive neurodegeneration following spinal cord injury. Neurology, 2018, 90, e1257-e1266.	1.1	97

#	Article	IF	CITATIONS
55	Mapping innate and adaptive immune function in arbovirus infections. Immunology, 2018, 154, 1-2.	4.4	0
56	Functions of adiposeâ€resident immune subsets and the impact on metabolic syndrome. Immunology, 2018, 155, 405-406.	4.4	2
57	A Nobel Prizeâ€worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology, 2018, 155, 283-284.	4.4	53
58	Bioinformatics for immunologists. Immunology, 2018, 155, 1-2.	4.4	1
59	Regulatory Tâ€cells: receptors, repertoires and roles in disease. Immunology, 2018, 155, 153-154.	4.4	1
60	Establishing the new playbook for interactions among microbiota, bacterial metabolites, adaptive immunity, autoimmune disease and metabolic syndrome. Immunology, 2018, 154, 533-534.	4.4	0
61	Immune Control of Burkholderia pseudomallei––Common, High-Frequency T-Cell Responses to a Broad Repertoire of Immunoprevalent Epitopes. Frontiers in Immunology, 2018, 9, 484.	4.8	15
62	Lung Defense through IL-8 Carries a Cost of Chronic Lung Remodeling and Impaired Function. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 557-571.	2.9	48
63	Neuroimmunology and neuroinflammation in autoimmune, neurodegenerative and psychiatric disease. Immunology, 2018, 154, 167-168.	4.4	13
64	New tools for <scp>MHC</scp> research from machine learning and predictive algorithms to the tumour immunopeptidome. Immunology, 2018, 154, 329-330.	4.4	3
65	Infection with Burkholderia pseudomallei – immune correlates of survival in acute melioidosis. Scientific Reports, 2017, 7, 12143.	3.3	42
66	Guillain-Barré syndrome and arboviral infection in Brazil. Lancet Infectious Diseases, The, 2017, 17, 693-694.	9.1	13
67	Canonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C. Frontiers in Immunology, 2017, 8, 193.	4.8	40
68	CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal Factor. Frontiers in Microbiology, 2016, 6, 1506.	3.5	11
69	BIITE: A Tool to Determine HLA Class II Epitopes from T Cell ELISpot Data. PLoS Computational Biology, 2016, 12, e1004796.	3.2	4
70	Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 523-554.	22.4	84
71	KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells. European Journal of Immunology, 2016, 46, 185-191.	2.9	23
72	Natural cutaneous anthrax infection, but not vaccination, induces a CD4+ T cell response involving diverse cytokines. Cell and Bioscience, 2015, 5, 20.	4.8	7

#	Article	IF	CITATIONS
73	Whole genome protein microarrays for serum profiling of immunodominant antigens of Bacillus anthracis. Frontiers in Microbiology, 2015, 6, 747.	3.5	9
74	MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity. BMC Neurology, 2015, 15, 72.	1.8	9
75	Host immunity to <i>Bacillus anthracis</i> lethal factor and other immunogens: implications for vaccine design. Expert Review of Vaccines, 2015, 14, 429-434.	4.4	11
76	Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infectious Diseases, The, 2015, 15, 840-851.	9.1	107
77	Anthrax in injecting drug users: the need for increased vigilance in the clinic. Expert Review of Anti-Infective Therapy, 2015, 13, 681-684.	4.4	13
78	Autoantigen cross-reactive environmental antigen can trigger multiple sclerosis-like disease. Journal of Neuroinflammation, 2015, 12, 91.	7.2	3
79	Chronic Infection by Mucoid <i>Pseudomonas aeruginosa</i> Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1250-1264.	5.6	27
80	Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized―Multiple Sclerosis-like Disease. Journal of Biological Chemistry, 2015, 290, 15260-15278.	3.4	7
81	T Cell Immunity to the Alkyl Hydroperoxide Reductase of <i>Burkholderia pseudomallei</i> : A Correlate of Disease Outcome in Acute Melioidosis. Journal of Immunology, 2015, 194, 4814-4824.	0.8	44
82	Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax, 2014, 69, 335-345.	5.6	13
83	Anthrax Lethal Factor as an Immune Target in Humans and Transgenic Mice and the Impact of HLA Polymorphism on CD4+ T Cell Immunity. PLoS Pathogens, 2014, 10, e1004085.	4.7	18
84	CD4+ T Cell Epitopes of FliC Conserved between Strains of <i>Burkholderia</i> : Implications for Vaccines against Melioidosis and Cepacia Complex in Cystic Fibrosis. Journal of Immunology, 2014, 193, 6041-6049.	0.8	27
85	The serodominant secreted effector protein of <i>Salmonella</i> , SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse <scp>HLA</scp> class <scp>II</scp> alleles. Immunology, 2014, 143, 438-446.	4.4	32
86	Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis. Neurology, 2014, 83, 1321-1325.	1.1	24
87	Elongated TCR alpha chain CDR3 favors an altered CD4 cytokine profile. BMC Biology, 2014, 12, 32.	3.8	4
88	Injectional anthrax infection due to heroin use induces strong immunological memory. Journal of Infection, 2014, 68, 200-203.	3.3	10
89	Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response. Acta Neuropathologica, 2013, 126, 501-515.	7.7	32
90	Anthrax Lethal Toxin and the Induction of CD4 T Cell Immunity. Toxins, 2012, 4, 878-899.	3.4	9

#	Article	IF	CITATIONS
91	Comment on "Frequency of Epitope-Specific Naive CD4+ T Cells Correlates with Immunodominance in the Human Memory Repertoire― Journal of Immunology, 2012, 188, 5205-5206.	0.8	1
92	Increased <scp>HLA</scp> ‣ expression in white matter lesions in multiple sclerosis. Immunology, 2012, 137, 317-325.	4.4	24
93	Immune regulation in idiopathic bronchiectasis. Annals of the New York Academy of Sciences, 2012, 1272, 68-72.	3.8	8
94	Innate Immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1). Journal of Neuroinflammation, 2012, 9, 1.	7.2	147
95	Charcot–Marie–Tooth disease associated with recurrent optic neuritis. Journal of Clinical Neuroscience, 2011, 18, 1422-1423.	1.5	7
96	CD4 ⁺ T ell immunity to the <i>Burkholderia pseudomallei</i> ABC transporter LolC in melioidosis. European Journal of Immunology, 2011, 41, 107-115.	2.9	8
97	Natural Exposure to Cutaneous Anthrax Gives Long-Lasting T Cell Immunity Encompassing Infection-Specific Epitopes. Journal of Immunology, 2010, 184, 3814-3821.	0.8	45
98	Repertoire of HLA-DR1-Restricted CD4 T-Cell Responses to Capsular Caf1 Antigen of <i>Yersinia pestis</i> in Human Leukocyte Antigen Transgenic Mice. Infection and Immunity, 2010, 78, 4356-4362.	2.2	17
99	An Epitope of Bacillus anthracis Protective Antigen That Is Cryptic in Rabbits May Be Immunodominant in Humans. Infection and Immunity, 2010, 78, 2353-2354.	2.2	11
100	HLA-DR Alleles in Amyloid β-Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele. Journal of Immunology, 2009, 183, 3522-3530.	0.8	48
101	HLA-DQB1*0602 Determines Disease Susceptibility in a New "Humanized―Multiple Sclerosis Model in HLA-DR15 (DRB1*1501;DQB1*0602) Transgenic Mice. Journal of Immunology, 2009, 183, 3531-3541.	0.8	27
102	A role of cellular prion protein in programming T ell cytokine responses in disease. FASEB Journal, 2009, 23, 1672-1684.	0.5	22
103	In Vivo Enhancement of Peptide Display by MHC Class II Molecules with Small Molecule Catalysts of Peptide Exchange. Journal of Immunology, 2009, 182, 6342-6352.	0.8	31
104	Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression. Journal of Experimental Medicine, 2009, 206, 1535-1547.	8.5	192
105	Review series on helminths, immune modulation and the hygiene hypothesis: Nematode coevolution with adaptive immunity, regulatory networks and the growth of inflammatory diseases. Immunology, 2009, 126, 1-2.	4.4	10
106	Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma. Journal of Allergy and Clinical Immunology, 2009, 124, 860-862.	2.9	37
107	Regulation, FoxP3, Suppression and Immunity. Immunology, 2008, 123, 1-2.	4.4	2
108	The cellular prion protein is preferentially expressed by CD4 ⁺ â€fCD25 ⁺ â€fFoxp3 ⁺ regulatory T cells. Immunology, 2008, 125, 313-319.	4.4	18

#	Article	IF	CITATIONS
109	Pulmonary Infection with <i>Cryptococcus neoformans</i> in the Face of Underlying Sarcoidosis. Respiration, 2007, 74, 462-466.	2.6	12
110	The Human Prion Protein Residue 129 Polymorphism Lies Within a Cluster of Epitopes for T Cell Recognition. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1059-1068.	1.7	4
111	HLA-C and Killer Cell Immunoglobulin-like Receptor Genes in Idiopathic Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 327-333.	5.6	67
112	Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood, 2005, 105, 2175-2179.	1.4	60
113	Spread of T Lymphocyte Immune Responses to Myelin Epitopes With Duration of Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2005, 64, 371-377.	1.7	24
114	Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. International Immunology, 2005, 17, 1157-1165.	4.0	26
115	Antagonist peptide for the treatment of bacterial superantigen toxic shock in a clinical or biowarfare setting. Expert Opinion on Therapeutic Patents, 2005, 15, 741-743.	5.0	1
116	High Incidence of Spontaneous Disease in an HLA-DR15 and TCR Transgenic Multiple Sclerosis Model. Journal of Immunology, 2005, 174, 1938-1946.	0.8	74
117	The Mechanism of Superantigen-Mediated Toxic Shock: Not a Simple Th1 Cytokine Storm. Journal of Immunology, 2005, 175, 6870-6877.	0.8	106
118	Developing vaccines to counter bioterrorist threats. Expert Review of Vaccines, 2005, 4, 275-279.	4.4	2
119	Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11749-11754.	7.1	40
120	Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. European Journal of Immunology, 2004, 34, 1839-1848.	2.9	52
121	Models of multiple sclerosis. Drug Discovery Today: Disease Models, 2004, 1, 405-410.	1.2	7
122	Reciprocal conditioning: T cells as regulators of dendritic cell function. Immunology, 2003, 109, 473-475.	4.4	1
123	CD4 T Cells Selected by Antigen Under Th2 Polarizing Conditions Favor an Elongated TCRα Chain Complementarity-Determining Region 3. Journal of Immunology, 2002, 168, 1018-1027.	0.8	17
124	Is selection for TCR affinity a factor in cytokine polarization?. Trends in Immunology, 2002, 23, 526-529.	6.8	58
125	The case against epitope spread in experimental allergic encephalomyelitis. Immunological Reviews, 1998, 164, 101-110.	6.0	15
126	Biochemical characterization of the human diabetes-associated HLA-DQ8 allelic product: Similarity to the major histocompatibility complex class II I-Ag7 protein of non-obese diabetic mice. European Journal of Immunology, 1997, 27, 2478-2483.	2.9	32

#	Article	IF	CITATIONS
127	Relapsing and remitting experimental allergic encephalomyelitis: A focused response to the encephalitogenic peptide rather than epitope spread. European Journal of Immunology, 1997, 27, 2927-2934.	2.9	28
128	Non-obese diabetic mice hemizygous at the T cell receptor α locus are susceptible to diabetes and sialitis. European Journal of Immunology, 1996, 26, 953-956.	2.9	28
129	Exacerbated autoimmunity associated with a T helper-1 cytokine profile shift in H-2E-transgenic mice. European Journal of Immunology, 1995, 25, 3134-3141.	2.9	21
130	Update: HLA-DQ Associations with Autoimmune Disease. Autoimmunity, 1993, 14, 79-83.	2.6	13
131	Mouse mammary tumor virus-mediated T-cell receptor negative selection in HLA-DRA transgenic mice. Human Immunology, 1993, 37, 149-156.	2.4	11